This is a working overview of acetylated peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-05. Anything still debated is marked as such rather than presented as settled.
Full-length thymosin beta-4 consists of roughly forty-three amino acids and ranks among the more abundant small proteins in the cytoplasm. The fragment is much shorter, so it cannot reproduce every function attributed to the intact molecule. In cell culture, short actin-binding motifs can interfere with filament dynamics and cell movement, but such observations come from controlled experiments rather than from whole-animal work. Whether a truncated fragment produces the same effects as the parent protein remains an open question.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
| Property | Value | Notes |
|---|---|---|
| Generic designation | Synthetic thymosin beta-4 N-terminal fragment | Peptide nomenclature varies by supplier |
| Peptide length | Approximately 17 amino acid residues | Reported length sometimes differs between sources |
| N-terminal modification | Acetyl group | Affects mass and chromatographic behaviour |
| Compound class | Small synthetic peptide | Not a small-molecule drug |
| Common synonyms | TB4 fragment; thymosin beta-4 fragment | Naming is inconsistent in popular media |
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
== Clinical significance relevance == The protein UBC9 encoded by the UBE2I gene has been shown to be targeted by multiple viruses, including HIV and HPV. It has been hypothesized that these viruses hijack UBC9 to serve their own purposes.
Iraqi commandos infiltrated the Kuwaiti border first to prepare for the major units, which began the attack at midnight. The Iraqi attack had two prongs, with the primary attack force driving south straight for Kuwait City down the main highway, and a supporting attack force entering Kuwait farther west, but then turning and driving east, cutting off Kuwait City from the country's southern half. The commander of a Kuwaiti armored battalion, 35th Armoured Brigade, deployed them against the Iraqi attack and conducted a robust defense at the Battle of the Bridges near Al Jahra, west of Kuwait City. Kuwaiti aircraft scrambled to meet the invading force, but approximately 20% were lost or captured. A few combat sorties were flown against Iraqi ground forces. The main Iraqi thrust into Kuwait City was conducted by commandos deployed by helicopters and boats to attack the city from the sea, while other divisions seized the airports and two airbases. The Iraqis attacked the Dasman Palace, the Royal Residence of Kuwait's emir, Jaber Al-Ahmad Al-Jaber Al-Sabah, which was defended by the Emiri Guard supported with M-84 tanks. In the process, the Iraqis killed Fahad Al-Ahmed Al-Jaber Al-Sabah, the Emir's youngest brother. Within 12 hours, most resistance had ended within Kuwait, and the royal family had fled, allowing Iraq to control most of Kuwait. After two days of intense combat, most of the Kuwaiti military were either overrun by the Iraqi Republican Guard, or had escaped to Saudi Arabia. The emir and key ministers fled south along the highway for refuge in Saudi Arabia.
== History == Before the development of the ELISA, the only option for conducting an immunoassay was radioimmunoassay, a technique using radioactively labeled antigens or antibodies. In radioimmunoassay, the radioactivity provides the signal, which indicates whether a specific antigen or antibody is present in the sample. Radioimmunoassay was first described in a scientific paper by Rosalyn Sussman Yalow and Solomon Berson published in 1960. As radioactivity poses a potential health threat, a safer alternative was sought. A suitable alternative to radioimmunoassay would substitute a nonradioactive signal in place of the radioactive signal. When enzymes (such as horseradish peroxidase) react with appropriate substrates (such as ABTS or TMB), a change in color occurs, which is used as a signal. However, the signal has to be associated with the presence of an antibody or antigen, which is why the enzyme has to be linked to an appropriate antibody. This linking process was independently developed by Stratis Avrameas and G. B. Pierce. Since it is necessary to remove any unbound antibody or antigen by washing, the antibody or antigen has to be fixed to the surface of the container; i.e., the immunosorbent must be prepared. A technique to accomplish this was published by Wide and Jerker Porath in 1966. In 1971, Peter Perlmann and Eva Engvall at Stockholm University in Sweden, and Anton Schuurs and Bauke van Weemen in the Netherlands independently published papers that synthesized this knowledge into methods to perform EIA/ELISA.
== Chemistry == Analysis using reversed phase high performance liquid chromatography showed that there was great similarity in chemical constituents of leaves of the hybrid compared to those of its parents (Chan & Wong, 2009). Peak areas were intermediate in R. × lamarckii with higher values in R. stylosa and lower values in R. apiculata. One of the compounds identified in the leaves of the hybrid and its parents was rutin.
Narrated by Juliet Stevenson (later to narrate many Horizon documentaries), directed by John Simmons, produced by Martine Benoit, made by Geofilms 27 September How They Built the Channel Tunnel, looking at the construction of the two crossover places of the tunnel, as big as two football fields, forty metres below the sea bed; AR Dykes, the President of the British Institution of Structural Engineers in 1976; Gordon Crighton, engineering director of TML, David Wallis, project manager of UK Tunnels of TML; the French end of the tunnel was at Beussingue; it took five years; Colin Kirkland, technical director of Eurotunnel; Richard Lewis of Markhams, a steel fabricator in Chesterfield; geologist Malcolm Bolton of the University of Cambridge; Douglas Parkes of Ove Arup; Stewart Campbell of the HSE; tunnelling began from Folkestone in October 1987; many tunnellers were from North East England and the Irish, such as Jim Ahern; 2,000 tonnes of chalk per hour came out of the tunnel during 1989; the laser guidance was made by Zed Systems of London; 440 metres of tunnel per week could be built; tunnel concrete segments were cast on the Isle of Grain, in Kent; nine workers died in accidents - seven on the English side; there are two cross-over caverns; the English cavern was built from the service tunnel, before the main tunnels arrived; the caverns are 21 metres wide, 16 metres high and 147 metres long, with two movable walls; the British Tunnelling Society; Alan Myers, construction manager of the crossover for UK Tunnels; civil engineer John King.
Sources: en.wikipedia.org
AMPylation of the IbpA Fic domain of Rho family GTPases is responsible for its cytotoxicity. Both Fic domains have similar effects on host cells' cytoskeleton as VopS. The AMPylation on a tyrosine residue of the switch 1 region blocks the interaction of the GTPases with downstream substrates such as PAK. DrrA is the Dot/Icm type IV translocation system substrate DrrA from Legionella pneumophila. It is the effector secreted by L. pneumophila to modify GTPases of the host cells. This modification increases the survival of bacteria in host cells. DrrA is composed of Rab1b specific guanine nucleotide exchange factor (GEF) domain, a C-terminal lipid binding domain and an N-terminal domain with unclear cytotoxic properties. Research works show that N-terminal and full-length DrrA shows AMPylators activity toward host's Rab1b protein (Ras related protein), which is also the substrate of Rab1b GEF domain. Rab1b protein is the GTPase Rab to regulate vesicle transportation and membrane fusion. The adenylation by bacteria AMPylators prolong GTP-bound state of Rab1b. Thus, the role of effector DrrA is connected toward the benefits of bacteria's vacuoles for their replication during the infection.
=== Humans and other mammals === Humans and other mammals have chitinase and chitinase-like proteins that can degrade chitin; they also possess several immune receptors that can recognize chitin and its degradation products, initiating an immune response. Chitin is sensed mostly in the lungs or gastrointestinal tract where it can activate the innate immune system through eosinophils or macrophages, as well as an adaptive immune response through T helper cells. Keratinocytes in skin can also react to chitin or chitin fragments.
4 March COVID-19 in the UK: Lockdown Files: The latest leaked WhatsApp messages published by the Daily Telegraph indicate, according to BBC News who have not seen or verified the messages, that Matt Hancock and his staff deliberated over whether or not he had broken COVID-19 regulations after pictures of him kissing his aide, Gina Coladangelo, were published by The Sun newspaper. Other messages also show Hancock criticising the Eat Out to Help Out scheme for "causing problems" in areas where there were a high number of COVID-19 cases. Typhoon jets are scrambled from RAF Coningsby in Lincolnshire to help escort a civilian plane en route from Iceland to Kenya following a loss of communication caused by an equipment malfunction. A sonic boom is heard over parts of England after the jets are allowed to fly at supersonic speed. 5 March Train fares in England and Wales are increased by up to 5.9%, representing the largest increase in more than a decade. COVID-19 in the UK: Lockdown Files: News outlets including BBC News, Sky News and The Independent — who have not verified the messages — report that further WhatsApp messages published by The Telegraph appear to show discussions about how and when the government should reveal details of the Kent variant in order to ensure people would comply with COVID-19 regulations. The news outlets also say Hancock appears to suggest they should "frighten the pants off everyone", while in another conversation, head of the civil service Simon Case suggests the "fear/guilt factor" is an important element of the government's messaging.
=== Perrault method === This approach, discovered by Perrault and Chan in 2009, uses hydroquinone to reduce HAuCl4 in an aqueous solution that contains 15 nm gold nanoparticle seeds. This seed-based method of synthesis is similar to that used in photographic film development, in which silver grains within the film grow through addition of reduced silver onto their surface. Likewise, gold nanoparticles can act in conjunction with hydroquinone to catalyze reduction of ionic gold onto their surface. The presence of a stabilizer such as citrate results in controlled deposition of gold atoms onto the particles, and growth. Typically, the nanoparticle seeds are produced using the citrate method. The hydroquinone method complements that of Frens, as it extends the range of monodispersed spherical particle sizes that can be produced. Whereas the Frens method is ideal for particles of 12–20 nm, the hydroquinone method can produce particles of at least 30–300 nm.
Myomesin is a protein family found in the M-line of the sarcomere structure. Myomesin has various forms throughout the body in striated muscles with specialized functions. This includes both slow and fast muscle fibers. Myomesin are made of 13 domains including a unique N-terminal followed by two immunoglobulin-like (Ig) domains, five fibronectin type III (Fn) domains, five more Ig domains. These domains all promote binding which indicates that myomesin is regulated through binding.
Sources: en.wikipedia.org
It is a synthetic peptide based on a short sequence near the start of thymosin beta-4. It is supplied as a research chemical rather than as a licensed pharmaceutical product.
No. Thymosin beta-4 is the full-length protein of about forty-three amino acids, while the fragment covers only its beginning. The two are related but are not interchangeable in experimental or analytical terms.
The label is a catalogue designation that became common in non-technical discussion. Scientific papers usually refer to the fragment by sequence or as a thymosin beta-4 N-terminal peptide.
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.